Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol

10 Moments That Changed HIV Care This Year

December 13, 2013

 3/12 

Sustiva Consternation

Sustiva Consternation

As you just read on the previous page, integrase inhibitors are on the rise. Does this mean that the long-standing dominance of Sustiva (efavirenz, Stocrin) -- one of the key drugs in Atripla (efavirenz/tenofovir/FTC) -- is coming to an end?

It's much too soon to count Sustiva out; it remains a very potent drug that works wonderfully for a large number of people. But there's no denying that Sustiva's place at the apex of HIV medication mountain got more shaky this year.

One of the key moments in this evolution may have taken place during a research conference in October, where a study revealed that long-term use of Sustiva appeared to be linked with a higher suicide rate. Although the overall rates of suicide in the study were still extremely low, the finding nonetheless cast a new shadow on a drug that has sometimes been associated with neurological side effects.

Read the full story >>




Related Stories

2013 Year in Review: Features and News

This article was provided by TheBody.com.
 

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement